Brief: Imugene Licenses Allogeneic Cd19 Car T Cell Therapy
16/08/2023 01:58
Aug 16 (Reuters) - Imugene Ltd IMU.AX :
* LICENSES ALLOGENEIC CD19 CAR T CELL THERAPY
* ENTERED INTO AN AGREEMENT WITH PRECISION BIOSCIENCES,
Source text for Eikon: ID:nASX6gf4GD
Further company coverage: IMU.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Imugene
See all newsAustralia's Imugene rises on fresh responses in blood cancer drug trial
Brief: Imugene Ltd Says Leslie Chong Resigns As CEO
Australia's Imugene loses most in over 8-years on discounted placement
Brief: Imugene To Raise A$11.12 Million Via Placement At A$0.095 Per Share
Brief: Imugene Requests Trading Halt Pending Proposed Capital Raising Announcement